

P687

Is sacubitril/valsartan useful in patients with cancer and heart failure? Data from HF-COH Spanish multicenter registry

A. Martin Garcia¹, C. Mitroi², M. Chaparro³, P. Moliner⁴, A. Martinez-Monzonis⁵, A.C. Martin-Garcia¹, C. Asla⁶, A. Castro³, F. Gual-Capllonch⁴, I. Marco⁶, C. Sanchez-Pablo¹, M. Antunez Ballesteros¹, J.L. Lopez Sendon⁶, P.L. Sanchez¹, T. Lopez-Fernandez⁶

¹Hospital Universitario de Salamanca-IBSAL-CIBERCV, Cardiology Department., Salamanca, Spain; ²University Hospital Puerta de Hierro Majadahonda, Cardiology, Madrid, Spain; ³Virgen de la Macarena Hospital, Cardiology, Sevilla, Spain; ⁴Germans Trias i Pujol Hospital, Cardiology, Badalona (Barcelona), Spain; ⁵University Hospital of Santiago de Compostela, Cardiology, Santiago de Compostela, Spain; ⁶University Hospital La Paz, Madrid, Spain

On behalf of Spanish National Cardio-Oncology Working Group

Current guidelines recommend sacubitril/valsartan (S/V) for patients (p.) with heart failure and reduced left ventricular ejection fraction (LVEF) but there is lack of evidence of its efficacy and safety in p. with cancer and heart failure. Our aim was to analyze the potential benefit of S/V in specific cardio-oncology clinics.

Methods: We performed a retrospective multicenter registry (HF-COH) in six Spanish hospitals with cardio-oncology clinics including all p. treated with S/V. Clinical and echocardiographic data, NYHA functional class, type of neoplasms and anti-tumoral treatment were described. Median follow-up was 7.2 [7.9] months.

Results: Sixty-one p. were included (median age was 64 [21] years old; 64% women, 43% hypertensive, 54% dyslipidemics and 28% diabetics). Most of p. (97%) had cancer therapy related cardiac dysfunction (CTRD) with a median time from anti-cancer therapy to CTRD of 40 [132] months. Breast (46%) and hematological (38%) cancers were the most frequent

neoplasms, 31% of p. had metastatic disease and 71% had been treated with anthracyclines. In 5% S/V was initiated at CTRCD diagnosis while in 95% S/V was started to improve clinical status in p. already treated with ACE inhibitors or ARBs. 87% were on beta-blocker therapy and 74% on mineralocorticoid receptor antagonists. Maximal S/V titration dose was achieved in 8.2% of p. (24/26mg: 43%; 49/51mg: 33%) S/V was discontinued in 4 p. (reasons: 2 hypotension; 1: renal failure; 1: pruritus) Baseline NT-proBNP levels, functional class, and LVEF improved at the end of follow-up in p. who continued with S/V (all p values ≤ 0.01). No statistical differences were found in creatinine clearance or potassium serum levels. Table

Conclusions: Our experience suggests that S/V is well tolerated and improves functional class and left ventricular function parameters in patients with CTRCD.

Patient parameters before and after S/V

	Before S/V	After S/V	P value
LVEF (%)	33 [7]	39.5 [15]	<0.001
Creatinine (mg/dl)	0.9 [0.4]	0.9 [0.5]	0.15
Creatinine clearance (ml/min)	73 [30]	75 [37]	0.22
Potassium serum levels (mg/dl)	4.5 [0.5]	4.5 [0.6]	0.42
Systolic arterial pressure (mmHg)	116 [23]	112 [27]	0.025
Diastolic arterial pressure (mmHg)	70 [13]	68 [10]	0.498
NT-proBNP (pg/ml)	1831 [3132]	842 [1919]	0.007
NYHA	2.2±0.6	1.6±0.62	<0.001

Values are median [interquartile range] or mean \pm standard derivation; S/V: sacubitril-valsartan; LVEF: left ventricle ejection fraction.